Belz, Michael
Hessmann, Philipp
Vogelgsang, Jonathan
Schmidt, Ulrike
Ruhleder, Mirjana
Signerski-Krieger, Jörg
Radenbach, Katrin
Trost, Sarah
Schott, Björn H.
Wiltfang, Jens
Wolff-Menzler, Claus
Bartels, Claudia http://orcid.org/0000-0003-3023-9971
Funding for this research was provided by:
Georg-August-Universität Göttingen
Article History
Received: 22 January 2021
Accepted: 22 April 2021
First Online: 3 May 2021
Declarations
:
: All authors report no financial relationships with commercial interests related to this article. Beyond that, CB receives honoraria as a diagnostic consultant for Boehringer Ingelheim. CWM advises Janssen Cilag and LivaNova on an honorary basis. He advises the following hospitals and the hospital company: Amelung Klinik, hospital company: Mecklenburg-Vorpommern, Berlin-Brandenburg, Niedersachsen. CWM completes seminars for: mibeg institutes, PKM. JW is supported by an Ilídio Pinho professorship, iBiMED (UIDB/04501/2020) at the University of Aveiro, Portugal. JW is an advisory board member of Abbott, Biogen, Boehringer Ingelheim, Immunogenetics, Lilly, MSD Sharp & Dohme, and Roche Pharma. JW received honoraria for lectures from the AGNP, Actelion, Amgen, Beeijing Yibai Science and Technology Ltd., CSF-Society, Helios Klinikum Wuppertal, Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, Vitos Kurhessen-Bad Emstal, as well as funding from the German Federal Ministry for Education and Research (BMBF), the European Union (EU), and the German Research Foundation (DFG). JW holds the following patents: PCT/EP 2011 001724 and PCT/EP 2015 052945.
: Please see section “study sample” for details.
: The study complies with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects/patients were approved by the ethics committee of the University Medical Center Goettingen, Germany (#36/4/20).